177 related articles for article (PubMed ID: 18538698)
1. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin.
Shang D; Liu Y; Matsui Y; Ito N; Nishiyama H; Kamoto T; Ogawa O
Urology; 2008 Jun; 71(6):1220-5. PubMed ID: 18538698
[TBL] [Abstract][Full Text] [Related]
2. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
Shang D; Ito N; Kamoto T; Ogawa O
Urology; 2007 May; 69(5):1007-12. PubMed ID: 17482960
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
4. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines.
Shang D; Liu Y; Liu Q; Zhang F; Feng L; Lv W; Tian Y
Cancer Lett; 2009 Jun; 278(1):82-7. PubMed ID: 19168279
[TBL] [Abstract][Full Text] [Related]
5. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
Karam JA; Fan J; Stanfield J; Richer E; Benaim EA; Frenkel E; Antich P; Sagalowsky AI; Mason RP; Hsieh JT
Int J Cancer; 2007 Apr; 120(8):1795-802. PubMed ID: 17230511
[TBL] [Abstract][Full Text] [Related]
6. 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression.
Shang D; Liu Y; Xu X; Han T; Tian Y
Cancer Lett; 2011 Dec; 311(2):230-6. PubMed ID: 21880414
[TBL] [Abstract][Full Text] [Related]
7. 5-Aza-2'-Deoxycytidine and CDDP Synergistically Induce Apoptosis in Renal Carcinoma Cells via Enhancing the APAF-1 Activity.
Zhu X; Yi F; Chen P; Chen L; Zhang X; Cao C; Tan W
Clin Lab; 2015; 61(12):1821-30. PubMed ID: 26882803
[TBL] [Abstract][Full Text] [Related]
8. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
Shang D; Ito N; Watanabe J; Awakura Y; Nishiyama H; Kamoto T; Ogawa O
Eur Urol; 2007 Oct; 52(4):1131-9. PubMed ID: 17275163
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
Anzai H; Frost P; Abbruzzese JL
Cancer Res; 1992 Apr; 52(8):2180-5. PubMed ID: 1373105
[TBL] [Abstract][Full Text] [Related]
10. 5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells.
Gomyo Y; Sasaki J; Branch C; Roth JA; Mukhopadhyay T
Oncogene; 2004 Sep; 23(40):6779-87. PubMed ID: 15273730
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
[TBL] [Abstract][Full Text] [Related]
12. 14-3-3σ mediates G2-M arrest produced by 5-aza-2'-deoxycytidine and possesses a tumor suppressor role in endometrial carcinoma cells.
Steiner M; Clark B; Tang JZ; Zhu T; Lobie PE
Gynecol Oncol; 2012 Oct; 127(1):231-40. PubMed ID: 22772061
[TBL] [Abstract][Full Text] [Related]
13. Emetine dihydrochloride: a novel therapy for bladder cancer.
Foreman KE; Jesse JN; Kuo PC; Gupta GN
J Urol; 2014 Feb; 191(2):502-9. PubMed ID: 24045224
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
15. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M; Oya M
Urology; 2009 Mar; 73(3):655-60. PubMed ID: 19167032
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Bai T; Tanaka T; Yukawa K; Umesaki N
Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
[TBL] [Abstract][Full Text] [Related]
18. The epigenetically regulated effects of Wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24).
Varol N; Konac E; Onen IH; Gurocak S; Alp E; Yilmaz A; Menevse S; Sozen S
DNA Cell Biol; 2014 Jul; 33(7):408-17. PubMed ID: 24665856
[TBL] [Abstract][Full Text] [Related]
19. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of invasive bladder cancer].
Kotake T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
